Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Drug Type
- Biotech
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Shanxi Province Cancer Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT06178601
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, 北京, Beijing, China
🇨🇳Shanxi Province Cancer Hospital, Taiyuan, Shanxi, China
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06178159
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
- Conditions
- Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast NeoplasmsHER2 Positive Breast NeoplasmsStomach NeoplasmsTriple Negative Breast NeoplasmsMetastatic Breast CancerMetastatic Gastric CancerAdvanced Breast CancerAdvanced Gastric Cancer
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 172
- Registration Number
- NCT06157892
- Locations
- 🇪🇸
Ecg Medica Sl, Valencia, Spain
🇺🇸Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
🇺🇸Banner-University Medical Center Tucson Campus, Tucson, Arizona, United States
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06155396
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Beijing Obstetrics and Gynecology Hospital ,Capital Medical University, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06155383
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳Shandong Cancer Hospital & Institute, Jinan, Shangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Registration Number
- NCT06105008
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳Binghe Xu, Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
🇨🇳Hunan Cancer Hospital, Changsha, China
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
- Conditions
- Gastric CancerHER2-low-expressing Gastric Cancer
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Shanghai East Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06078982
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-10
- Target Recruit Count
- 36
- Registration Number
- NCT06074484
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06063018
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
- Conditions
- Carcinoma, Non-Small-Cell LungOvarian NeoplasmsEndometrial NeoplasmsHead and Neck Neoplasms
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 119
- Registration Number
- NCT06003231
- Locations
- 🇺🇸
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, United States
🇩🇪Charite Campus Benjamin Franklin, Berlin, Germany
🇩🇪Charite Berlin-Campus Virchow, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.